Minimal residual disease in multiple myeloma: why, when, where - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34889430/
Improvements in multiple myeloma therapy have led to deeper responses that are beyond the limit of detection by historical immunohistochemistry and conventional flow cytometry in bone marrow samples. In parallel,...
Conclusion/Relevance: We review the data supporting MRD testing as well as its limitations and how it may fit in with current and future clinical practice.
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439722/
Katja Weisel, 1 Andrew Spencer, 2 Suzanne Lentzsch, 3 Hervé Avet-Loiseau, 4 Tomer M. Mark, 5 Ivan Spicka, 6 Tamas Masszi, 7 Birgitta Lauri, 8 Mark-David Levin, 9 Alberto Bosi,...
Conclusion: These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status.
Low levels of minimal residual disease after induction chemotherapy for BCR‐ABL1‐negative acute lymphoblastic leukaemia in adults are clinically relevant
Source : https://onlinelibrary.wiley.com/doi/10.1111/bjh.17966
Cyril Šálek , for the Czech Leukemia Study Group - for Life (CELL) , Corresponding Author Institute of Haematology and Blood Transfusion, Prague, Czech Republic Institute of Clinical and Experimental...
Conclusion/Relevance: The aim of the present study was to evaluate the significance of low-level minimal/measurable residual disease (MRD) during early consolidation treatment in adult BCR-ABL1–negative acute lymphoblastic leukaemia. The MRD load was monitored by immunoglobulin/T-cell receptor rearrangements and assessed as negative [complete...
History and Development of Autologous Stem Cell Transplantation for Acute Myeloid Leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34820613/
This review describes the development of cryopreservation, the birth of autologous stem cell transplantation (ASCT) and its past and present use to consolidate adult patients with acute myelogenous leukemia (AML)....
Conclusion/Relevance: This review describes the development of cryopreservation, the birth of autologous stem cell transplantation (ASCT) and its past and present use to consolidate adult patients with acute myelogenous leukemia (AML).
CAR-T cell therapy followed by unrelated cord blood transplantation for the treatment of relapsed/refractory B-cell ALL in children and young adults: superior survival but relatively high posttransplant relapse
Source : https://www.sciencedirect.com/science/article/pii/S2666636721013981?via=ihub
Available online 25 November 2021 * Bridging to UCBT after CAR-T therapy could improve OS, LFS and GRFS for children and young adults R/R B-cell ALL. * Cumulative incidence of...
/>
Conclusion: CAR-T therapy followed by UCBT produces superior survival in R/R B-ALL, but treated patients still exhibit a high posttransplant relapse rate.